EXAS
Exact Sciences Corporation
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$104.91
+0.00%Year over year
Reported trailing growth
- Revenue
- +17.7%
- EBITDA
- +105.3%
- EBIT
- +80.9%
- EPS
- +80.3%
- Free cash flow
- +378.6%
- Operating cash flow
- +133.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +15.9%
- EBITDA
- +104.5%
- EBIT
- +90.6%
- Net income
- +79.8%
- EPS
- +80.3%
- Free cash flow
- +234.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025